<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: We describe a new rabbit monoclonal antibody, raised against a fixation-resistant <z:chebi fb="0" ids="53000">epitope</z:chebi> of the transcription regulator LIM domain only 2 (LMO2) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS AND RESULTS: <z:hpo ids='HP_0002665'>Lymphoma</z:hpo> cell lines and a large series of <z:mpath ids='MPATH_458'>normal</z:mpath> and neoplastic samples were investigated by Western blot and immunohistochemistry </plain></SENT>
<SENT sid="2" pm="."><plain>The antibody detected nuclear positivity for the protein, with the exception of a proportion of classical Hodgkin <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HLs</z:e>), peripheral T cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PTCLs</z:e>) and <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumours</z:e> that showed granular cytoplasmic staining </plain></SENT>
<SENT sid="3" pm="."><plain>In <z:mpath ids='MPATH_458'>normal</z:mpath> lympho-haematopoietic tissues, LMO2 was expressed at different intensities by CD34(+) blasts, haematopoietic precursors, germinal centre (GC), mantle and splenic marginal zone B cells </plain></SENT>
<SENT sid="4" pm="."><plain>While reactive with only scattered elements in the thymus and nine of 237 PTCLs, the antibody stained 31 of 39 T-<z:hpo ids='HP_0011009'>acute</z:hpo> lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/<z:mpath ids='MPATH_336'>leukaemias</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALLs</z:e>) and the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e>-derived human leukaemic cell line, CCRF-CEM </plain></SENT>
<SENT sid="5" pm="."><plain>LMO2 was found in 88% of B-<z:hpo ids='HP_0011009'>acute</z:hpo> lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/<z:mpath ids='MPATH_336'>leukaemias</z:mpath> (<z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALLs</z:e>), 5% <z:hpo ids='HP_0011010'>chronic</z:hpo> lymphocytic <z:mpath ids='MPATH_336'>leukaemias</z:mpath> (CLLs) and 14%, 57% and 41% of mantle, follicular and Burkitt <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>In the setting of diffuse large B cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCLs</z:e>), LMO2-positivity was related strongly to a GC phenotype </plain></SENT>
<SENT sid="7" pm="."><plain>LMO2 was found in 83% primary mediastinal large B cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (PMBLs) and 100% nodular lymphocyte predominant Hodgkin <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NLPHLs</z:e>), whereas only 10% of classical <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HLs</z:e> were stained </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> and <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemias</z:mpath> were usually positive </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: The new anti-LMO2 antibody can be applied confidently to routine sections, contributing to the differential diagnosis of several <z:hpo ids='HP_0002665'>lymphoma</z:hpo> subtypes, subtyping of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCLs</z:e> and potential development of innovative therapies </plain></SENT>
</text></document>